Palivizumab
drugOn this page
Also known as MEDI-493SynagisSynagis abbosynagis
Summary
Palivizumab (CHEMBL1201586) is an approved antibody (ATC J06BD01); indicated across 4 conditions including respiratory system disorder and respiratory syncytial virus infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: J06BD01
- Indications: 4 conditions
- Clinical trials: 15
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201586 |
| Name | Palivizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | J06BD01 |
Also known as: MEDI-493, Palivizumab, Synagis, Synagis abbosynagis, PALIVIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| respiratory system disorder | 4 | MONDO:0005087 | EFO:0000684 |
| respiratory syncytial virus infectious disease | 4 | MONDO:0001577 | EFO:1001413 |
| bronchopulmonary dysplasia | 4 | MONDO:0019091 | MONDO:0019091 |
| congenital heart disease | 2 | MONDO:0005453 | EFO:0005207 |
Clinical trials
Total trials: 15.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 6 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE4 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00233064 | PHASE4 | COMPLETED | Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) |
| NCT00014391 | PHASE3 | COMPLETED | Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation |
| NCT00129766 | PHASE3 | COMPLETED | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| NCT01006629 | PHASE2/PHASE3 | COMPLETED | Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children |
| NCT01466062 | PHASE3 | COMPLETED | Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions |
| NCT02442427 | PHASE3 | COMPLETED | Palivizumab Therapy for RSV-bronchiolitis |
| NCT02968173 | PHASE3 | COMPLETED | A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus |
| NCT03959488 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children |
| NCT04938830 | PHASE3 | COMPLETED | Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) |
| NCT00113490 | PHASE1/PHASE2 | COMPLETED | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children |
| NCT00240929 | PHASE2 | COMPLETED | A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) |
| NCT00316264 | PHASE2 | COMPLETED | Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season |
| NCT00538785 | PHASE2 | COMPLETED | A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease |
| NCT04540627 | PHASE1 | COMPLETED | Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV |
| NCT06851806 | Not specified | RECRUITING | Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).